Cargando…

Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC(® )is a predictor for relapse: A preliminary report

BACKGROUND: Lung cancer still remains one of the most commonly occurring solid tumors and even in stage Ia, surgery fails in 30% of patients who develop distant metastases. It is hypothesized that these must have developed from occult circulating tumor cells present at the time of surgery, or before...

Descripción completa

Detalles Bibliográficos
Autores principales: Rolle, Axel, Günzel, Rainer, Pachmann, Ulrich, Willen, Babette, Höffken, Klaus, Pachmann, Katharina
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1087511/
https://www.ncbi.nlm.nih.gov/pubmed/15801980
http://dx.doi.org/10.1186/1477-7819-3-18
_version_ 1782123820139675648
author Rolle, Axel
Günzel, Rainer
Pachmann, Ulrich
Willen, Babette
Höffken, Klaus
Pachmann, Katharina
author_facet Rolle, Axel
Günzel, Rainer
Pachmann, Ulrich
Willen, Babette
Höffken, Klaus
Pachmann, Katharina
author_sort Rolle, Axel
collection PubMed
description BACKGROUND: Lung cancer still remains one of the most commonly occurring solid tumors and even in stage Ia, surgery fails in 30% of patients who develop distant metastases. It is hypothesized that these must have developed from occult circulating tumor cells present at the time of surgery, or before. The aim of the present study was to detect such cells in the peripheral blood and to monitor these cells following surgery. METHODS: 30 patients treated for lung cancer with surgery were monitored for circulating epithelial cells (CEC) by taking peripheral blood samples before, 2 weeks and 5 months after surgery and/or radiotherapy (RT) chemotherapy (CT) or combined RT/CT using magnetic bead enrichment and laser scanning cytometry (MAINTRAC(®)) for quantification of these cells. RESULTS: In 86% of the patients CEC were detected before surgery and in 100% at 2 weeks and 5 months after surgery. In the control group, which consisted of 100 normal donors without cancer, 97 % were negative for CEC. A significantly higher number of CEC was found preoperatively in patients with squamous cell carcinoma than in those with adenocarcinoma. In correlation to the extent of parenchymal manipulation 2 weeks after surgery, an increase in numbers of CEC was observed with limited resections (18/21) whereas pneumonectomy led to a decrease (5/8) of CEC, 2 weeks after surgery. The third analysis done 5 months after surgery identified 3 groups of patients. In the group of 5 patients who received neo- or adjuvant chemo/radiotherapy there was evidence that monitoring of CEC can evaluate the effects of therapy. Another group of 7 patients who underwent surgery only showed a decrease of CEC and no signs of relapse. A third group of 11 patients who had surgery only, showed an increase of CEC (4 with an initial decrease after surgery and 7 with continuous increase). In the group with a continuous increase during the following 24 months, 2 early relapses in patients with stage Ia adenocarcinoma were observed. The increase of CEC preceded clinical detection by six months. CONCLUSION: We consider, therefore, that patients with adenocarcinoma and a continuous increase of CEC after complete resection for lung cancer are at an increased risk of early relapse.
format Text
id pubmed-1087511
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-10875112005-04-28 Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC(® )is a predictor for relapse: A preliminary report Rolle, Axel Günzel, Rainer Pachmann, Ulrich Willen, Babette Höffken, Klaus Pachmann, Katharina World J Surg Oncol Research BACKGROUND: Lung cancer still remains one of the most commonly occurring solid tumors and even in stage Ia, surgery fails in 30% of patients who develop distant metastases. It is hypothesized that these must have developed from occult circulating tumor cells present at the time of surgery, or before. The aim of the present study was to detect such cells in the peripheral blood and to monitor these cells following surgery. METHODS: 30 patients treated for lung cancer with surgery were monitored for circulating epithelial cells (CEC) by taking peripheral blood samples before, 2 weeks and 5 months after surgery and/or radiotherapy (RT) chemotherapy (CT) or combined RT/CT using magnetic bead enrichment and laser scanning cytometry (MAINTRAC(®)) for quantification of these cells. RESULTS: In 86% of the patients CEC were detected before surgery and in 100% at 2 weeks and 5 months after surgery. In the control group, which consisted of 100 normal donors without cancer, 97 % were negative for CEC. A significantly higher number of CEC was found preoperatively in patients with squamous cell carcinoma than in those with adenocarcinoma. In correlation to the extent of parenchymal manipulation 2 weeks after surgery, an increase in numbers of CEC was observed with limited resections (18/21) whereas pneumonectomy led to a decrease (5/8) of CEC, 2 weeks after surgery. The third analysis done 5 months after surgery identified 3 groups of patients. In the group of 5 patients who received neo- or adjuvant chemo/radiotherapy there was evidence that monitoring of CEC can evaluate the effects of therapy. Another group of 7 patients who underwent surgery only showed a decrease of CEC and no signs of relapse. A third group of 11 patients who had surgery only, showed an increase of CEC (4 with an initial decrease after surgery and 7 with continuous increase). In the group with a continuous increase during the following 24 months, 2 early relapses in patients with stage Ia adenocarcinoma were observed. The increase of CEC preceded clinical detection by six months. CONCLUSION: We consider, therefore, that patients with adenocarcinoma and a continuous increase of CEC after complete resection for lung cancer are at an increased risk of early relapse. BioMed Central 2005-03-31 /pmc/articles/PMC1087511/ /pubmed/15801980 http://dx.doi.org/10.1186/1477-7819-3-18 Text en Copyright © 2005 Rolle et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Rolle, Axel
Günzel, Rainer
Pachmann, Ulrich
Willen, Babette
Höffken, Klaus
Pachmann, Katharina
Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC(® )is a predictor for relapse: A preliminary report
title Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC(® )is a predictor for relapse: A preliminary report
title_full Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC(® )is a predictor for relapse: A preliminary report
title_fullStr Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC(® )is a predictor for relapse: A preliminary report
title_full_unstemmed Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC(® )is a predictor for relapse: A preliminary report
title_short Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC(® )is a predictor for relapse: A preliminary report
title_sort increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by maintrac(® )is a predictor for relapse: a preliminary report
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1087511/
https://www.ncbi.nlm.nih.gov/pubmed/15801980
http://dx.doi.org/10.1186/1477-7819-3-18
work_keys_str_mv AT rolleaxel increaseinnumberofcirculatingdisseminatedepithelialcellsaftersurgeryfornonsmallcelllungcancermonitoredbymaintracisapredictorforrelapseapreliminaryreport
AT gunzelrainer increaseinnumberofcirculatingdisseminatedepithelialcellsaftersurgeryfornonsmallcelllungcancermonitoredbymaintracisapredictorforrelapseapreliminaryreport
AT pachmannulrich increaseinnumberofcirculatingdisseminatedepithelialcellsaftersurgeryfornonsmallcelllungcancermonitoredbymaintracisapredictorforrelapseapreliminaryreport
AT willenbabette increaseinnumberofcirculatingdisseminatedepithelialcellsaftersurgeryfornonsmallcelllungcancermonitoredbymaintracisapredictorforrelapseapreliminaryreport
AT hoffkenklaus increaseinnumberofcirculatingdisseminatedepithelialcellsaftersurgeryfornonsmallcelllungcancermonitoredbymaintracisapredictorforrelapseapreliminaryreport
AT pachmannkatharina increaseinnumberofcirculatingdisseminatedepithelialcellsaftersurgeryfornonsmallcelllungcancermonitoredbymaintracisapredictorforrelapseapreliminaryreport